RTP Mobile Logo
Submitted by web@researchtop... on Mon, 02/18/2019 - 15:05
DOU119

Interview with Michael A Postow, MD

Track 1: Mechanism of action of immune checkpoint inhibitors and rationale for combining anti-PD-1/PD-L1 and anti-CTLA-4 antibodies
Track 2: “Hot” versus “cold” tumors and effect of the tumor microenvironment on response to immunotherapy
Track 3: Correlation between tumor mutational burden and activity of immune checkpoint inhibitors
Track 4: PD-L1 expression as a predictive marker of benefit with combination immune checkpoint blockade for melanoma
Track 5: Perspective on the role of PD-L1 testing for patients with melanoma
Track 6: Efficacy and safety of combination versus single-agent immune checkpoint blockade in patients with melanoma and brain metastases
Track 7: Dosing considerations and adverse events associated with anti-PD-1/PD-L1 and anti-CTLA-4 antibody combinations
Track 8: Emerging data with novel anti-CTLA-4 antibodies under investigation for melanoma
Track 9: Efficacy of combined immune checkpoint blockade versus BRAF/MEK inhibitor combinations for patients with melanoma and BRAF tumor mutations
Track 10: Clinical presentation and frequency of hypophysitis associated with immune checkpoint blockade
Track 11: Monitoring and management of hypophysitis
Track 12: Immune-related adverse events in patients with melanoma
Track 13: Correlation between toxicity and benefit with checkpoint inhibitors
Track 14: Case: A 53-year-old man with metastatic mucosal melanoma discontinues the combination of ipilimumab and nivolumab because of immune-related adverse events
Track 15: Management of immune checkpoint inhibitor-associated thyroid dysfunction, hepatitis and pancreatitis
Track 16: Risks and benefits of radiation therapy for patients with melanoma and brain metastases
Track 17: Case: A 31-year-old woman presents with back pain and is diagnosed with metastatic melanoma with a BRAF tumor mutation
Track 18: UV radiation exposure from the sun as an etiologic factor for melanoma
Track 19: Choosing among the BRAF/MEK inhibitor combinations dabrafenib/trametinib, vemurafenib/cobimetinib and encorafenib/binimetinib for melanoma with a BRAF tumor mutation
Track 20: Side-effect profiles of BRAF/MEK inhibitor combinations
Track 21: Use of dabrafenib/trametinib and consolidation radiation therapy for patients with metastatic melanoma and BRAF tumor mutations
Track 22: Adjuvant therapy options for melanoma
Track 23: Case: A 72-year-old woman with a history of primary biliary cirrhosis presents with an ulcerated lesion on her left arm and a mass in her axilla and is diagnosed with Stage III melanoma
Track 24: Choosing between dabrafenib/trametinib and an anti-PD-1 antibody as adjuvant therapy for melanoma with a BRAF tumor mutation
Track 25: Understanding the mechanisms of autoimmune toxicities in patients receiving immunotherapy
Track 26: Perspective on the use of adjuvant therapy versus observation for patients with melanoma and BRAF tumor mutations

Interview with Karl Lewis, MD

Track 1: Case: A 75-year-old man who presents with a large mass on his right cheek is diagnosed with locally advanced squamous cell carcinoma (SCC) of the skin and receives pembrolizumab
Track 2: Pathophysiology and management of SCC of the skin
Track 3: Cemiplimab, a novel PD-1 antibody for locally advanced and metastatic SCC of the skin
Track 4: Activity and tolerability of cemiplimab observed in Phase I/II studies
Track 5: Pathogenesis of SCC of the skin and potential role of cemiplimab in management of this disease
Track 6: Durable responses to pembrolizumab in patients with SCC of the skin
Track 7: Emerging data with anti-PD-1 checkpoint inhibitors in combination with anti-LAG-3/TIM-3 antibodies
Track 8: Case: A 78-year-old man with recurrent, locally advanced basal cell carcinoma (BCC) receives the hedgehog inhibitor sonidegib
Track 9: Efficacy and tolerability of sonidegib
Track 10: Management of side effects associated with hedgehog inhibitors
Track 11: Comparison of the efficacy and side-effect profiles of vismodegib and sonidegib
Track 12: Case: A 67-year-old man with metastatic Merkel cell carcinoma experiences a complete response to the anti-PD-L1 antibody avelumab
Track 13: Biology and clinical presentation of Merkel cell carcinoma
Track 14: JAVELIN Merkel 200 trial: Efficacy of avelumab in patients with metastatic Merkel cell carcinoma and disease progression on chemotherapy
Track 15: Perspective on the duration of immune checkpoint inhibitor therapy
Track 16: Ongoing investigation of immune checkpoint inhibitors for Merkel cell carcinoma in the (neo)adjuvant setting
Track 17: Case: A 30-year-old woman with Stage IIIB melanoma and a BRAF tumor mutation receives adjuvant pembrolizumab
Track 18: Efficacy of immune checkpoint inhibitors and BRAF/MEK inhibitor combinations as adjuvant therapy for Stage III/IV melanoma
Track 19: Choosing between a BRAK/MEK inhibitor combination and immune checkpoint blockade as adjuvant therapy for melanoma with a BRAF tumor mutation
Track 20: Case: A 65-year-old man with a long-standing nevus on his back is diagnosed with metastatic melanoma with a BRAF V600E mutation and receives dabrafenib/trametinib
Track 21: First-line therapeutic options for patients with metastatic melanoma and BRAF tumor mutations
Track 22: Results of the Phase III COLUMBUS trial: Efficacy and tolerability of encorafenib/binimetinib versus vemurafenib or encorafenib for unresectable or metastatic melanoma with a BRAF V600 mutation
Track 23: Management of dabrafenib/trametinib-associated side effects
Track 24: Case: A 53-year-old man receives first-line ipilimumab/nivolumab for metastatic melanoma
Track 25: Perspective on combination therapy versus monotherapy with immune checkpoint inhibitors for metastatic melanoma

Interview with Mario Sznol, MD

Track 1: Choosing between nivolumab and dabrafenib/trametinib as adjuvant therapy for melanoma with a BRAF tumor mutation
Track 2: Efficacy, tolerability and quality of life with adjuvant dabrafenib/trametinib and adjuvant nivolumab
Track 3: Updated results from the Phase III CheckMate 238 trial: Adjuvant nivolumab versus ipilimumab after complete resection of Stage III/IV melanoma
Track 4: Toxicity manifestations with anti-PD-1 antibodies alone and in combination with a CTLA-4 inhibitor
Track 5: Rare but potentially life-threatening complications associated with immune checkpoint inhibitors
Track 6: Monitoring and management of rare complications with immune checkpoint inhibitors
Track 7: Clinical experience with immune checkpoint inhibitor-associated colitis, pneumonitis and hepatitis
Track 8: General principles for managing adverse events in patients receiving immune checkpoint inhibitors
Track 9: Therapeutic approach to disease progression on an immune checkpoint inhibitor
Track 10: Duration of immune checkpoint inhibitor therapy for melanoma
Track 11: Perspective on the utility of immune checkpoint inhibitors for patients with preexisting autoimmune diseases
Track 12: Use of immune checkpoint inhibitor therapy after organ or allogeneic transplant
Track 13: Association between the gut microbiome and response to anti-PD-1 antibody therapy in metastatic melanoma
Track 14: Case: A 64-year-old man with newly diagnosed, symptomatic metastatic melanoma and a BRAF V600E mutation receives dabrafenib/trametinib
Track 15: Response rates with dabrafenib/trametinib and nivolumab/ipilimumab as first-line therapy for metastatic melanoma with a BRAF tumor mutation
Track 16: Switching to nivolumab/ipilimumab for patients experiencing a response to dabrafenib/trametinib
Track 17: Management of dabrafenib/trametinib-associated fevers
Track 18: Incidence of treatment-associated fevers with dabrafenib/trametinib and encorafenib/binimetinib
Track 19: Case: A 68-year-old man with metastatic melanoma and PD-L1 expression greater than 5% receives ipilimumab/nivolumab
Track 20: Testing for PD-L1 expression in patients with metastatic melanoma
Track 21: Clinical experience with immunotherapy-associated uveitis and vitiligo
Track 22: Case: A 47-year-old man with metastatic melanoma experiences dermatologic toxicity with ipilimumab/nivolumab
Track 23: Case: A 31-year-old man is diagnosed with metastatic mucosal melanoma
Track 24: Therapeutic options for patients with metastatic mucosal melanoma and a c-KIT mutation
Track 25: Activity and tolerability of ipilimumab/nivolumab in patients with metastatic mucosal melanoma

Interview with Prof Caroline Robert, MD, PhD

Track 1: Selection of adjuvant therapy for patients with melanoma and a BRAF tumor mutation
Track 2: Clinical benefit associated with adjuvant therapy with BRAF/MEK inhibitors and with immune checkpoint inhibitors for melanoma with a BRAF tumor mutation
Track 3: Use of immune checkpoint inhibitors for patients with preexisting autoimmune disease
Track 4: Safety profiles and duration of therapy with BRAF/MEK inhibitor combinations
Track 5: Tumor mutation burden and other potential biomarkers of response to adjuvant targeted therapy or immune checkpoint inhibition
Track 6: Emerging data with the novel IDO inhibitor epacadostat and anti-LAG-3 and anti-TIM-3 antibodies for metastatic melanoma
Track 7: Choosing between single-agent and combination immune checkpoint inhibitor therapy for metastatic melanoma
Track 8: Perspective on the association between immune-related adverse events and benefit from immune checkpoint inhibitors
Track 9: Duration of therapy and complete response rate with immunotherapy versus BRAF/MEK inhibitor combinations
Track 10: Case: A 27-year-old man with metastatic melanoma and a BRAF tumor mutation receives nivolumab/ipilimumab after experiencing disease progression on a BRAF/MEK inhibitor combination
Track 11: Efficacy and tolerability of BRAF/MEK inhibitor combinations
Track 12: Recent advances in the management of melanoma with metastases to the brain
Track 13: Clinical experience with hedgehog inhibitors for BCC
Track 14: Activity and side-effect profiles of sonidegib and vismodegib
Track 15: Activity of the PD-1 antibody cemiplimab in metastatic SCC of the skin
Track 16: Response to immune checkpoint inhibitors in patients with SCC of the skin
Track 17: Overview of Merkel cell carcinoma
Track 18: Response to PD-1/PD-L1 blockade in patients with Merkel cell carcinoma
 
FACULTY
 
Michael A Postow, MD
Medical Oncologist
Melanoma and Immunotherapeutics Service
Memorial Sloan Kettering Cancer Center
New York, New York
 
Karl Lewis, MD
Associate Professor of Medicine
Division of Medical Oncology
Director of the Melanoma
Research Clinics
University of Colorado Denver
Aurora, Colorado
 
Mario Sznol, MD
Professor of Medicine
Medical Oncology
Leader, Melanoma/Renal Cell Disease Research Team
Co-Leader
Cancer Immunology Program
Smilow Cancer Hospital
Yale New Haven Hospital
Yale University School of Medicine
New Haven, Connecticut
 
Professor Caroline Robert, MD, PhD
Chief, Dermato-Oncology
Co-Director, Melanoma Team INSERM
Gustave-Roussy Institute
Paris, France
 
EDITOR
 
Neil Love, MD
Research To Practice
Miami, Florida